Showing 4841-4850 of 21485 results for "".
- argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026https://reachmd.com/news/argenx-to-present-new-vyvgart-data-in-mg-and-cidp-plus-pipeline-results-at-aanem-2026/2488581/Key Takeaways argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. New
- Two Decades of Primary Mitochondrial Disease Trials: What Failed, What Worked, and What Comes Nexthttps://reachmd.com/news/two-decades-of-primary-mitochondrial-disease-trials-what-failed-what-worked-and-what-comes-next/2488587/Key Takeaways A structured scoping review and horizon scan in Therapeutic Advances in Rare Disease identified 71 interventional trials in primary mitochondrial disease (PMD) from 2000 to November 2025, across 25 countries. The au
- Dianthus Therapeutics to Present Claseprubart Data in CIDP and Myasthenia Gravis at AANEM 2026https://reachmd.com/news/dianthus-therapeutics-to-present-claseprubart-data-in-cidp-and-myasthenia-gravis-at-aanem-2026/2488578/Key Takeaways Dianthus Therapeutics will present claseprubart, an investigational complement inhibitor, in one oral and four poster presentations at the AANEM Annual Meeting, September 29 to October 2 in Orlando, Florida. The presentation
- Alma Academy 2026 Expands Focus Across Clinical Aesthetics, Business, and Beauty Culturehttps://reachmd.com/news/alma-academy-2026-expands-focus-across-clinical-aesthetics-business-and-beauty-culture/2488575/Alma North America has announced details for Alma Academy 2026, an expanded version of its educational event that will combine clinical aesthetics education with business strategy, beauty media, digital culture, and networking. The 4-day event is scheduled for Octobe
- Predictors of Early Relief After Cancer-Related Pain Procedureshttps://reachmd.com/news/early-relief-cancer-pain-procedures/2488568/Key Takeaways Among hospitalized patients with cancer-related pain undergoing a first inpatient interventional pain procedure, 25.5% were early overall responders within the 48-hour peri-procedural window. Higher baseline pain scores and lower baseline opioid doses w
- Researchers to Test Acceptance of Autonomous AI in Facial Surgery Planninghttps://reachmd.com/news/researchers-to-test-acceptance-of-autonomous-ai-in-facial-surgery-planning/2488573/Researchers for a forthcoming study will examine how increasing levels of artificial intelligence (AI) autonomy in facial reconstructive surgery planning affect public perceptions of acceptability, trust, risk, and responsibility. Publishing the study protocol in
- Sarepta Announces Duchenne Gene Therapy and Exon-Skipping Presentations at World Muscle Society Congresshttps://reachmd.com/news/sarepta-announces-duchenne-gene-therapy-and-exon-skipping-presentations-at-world-muscle-society-congress/2488566/Key Takeaways Sarepta Therapeutics will present six posters on its Duchenne muscular dystrophy (DMD) portfolio at the 31st Annual Congress of the World Muscle Society (WMS), September 29 to October 3 in Hiroshima, Japan. Five of the poste
- Capricor to Present 24-Month HOPE-3 Data for Deramiocel in Duchenne at WMS 2026https://reachmd.com/news/capricor-to-present-24-month-hope-3-data-for-deramiocel-in-duchenne-at-wms-2026/2488564/Key Takeaways Capricor Therapeutics will present 24-month data from its Phase 3 HOPE-3 study and open-label extension (OLE) of deramiocel at the 2026 World Muscle Society (WMS) Congress, September 29 to October 3 in Hiroshima, Japan. The
- Ractigen Therapeutics to Present First-in-Human RAG-18 Data in Duchenne at WMS 2026https://reachmd.com/news/ractigen-therapeutics-to-present-first-in-human-rag-18-data-in-duchenne-at-wms-2026/2488565/Key Takeaways Ractigen Therapeutics will present first-in-human findings for RAG-18, an investigational small activating RNA (saRNA) for Duchenne muscular dystrophy (DMD), as a late-breaking oral presentation at the World Muscle Society (WMS) Cong
- Haruharu Wonder Debuts Petal Pink, Ruby Red PDRN Lip Balmshttps://reachmd.com/news/haruharu-wonder-debuts-petal-pink-ruby-red-pdrn-lip-balms/2488561/Haruharu Wonder has expanded its Rose PDRN Peptide Glowy Balm line with 2 tinted shades, Petal Pink and Ruby Red, combining buildable color with a skincare-focused lip formula. Rose-Derived PDRN and Peptides Meet Tinted Lip Care According to the company, the